IRadimed Corporation
IRMD
$51.44
-$1.40-2.65%
| Weiss Ratings | IRMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Good | |||
| Risk Index | Fair | |||
| Risk Grade | C- | |||
| Reward Grade | B+ | |||
| Rating Factors | IRMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Weak | |||
| Growth Index | Excellent | |||
| Efficiency Index | Excellent | |||
| Solvency Index | Excellent | |||
| Total Return Index | Fair | |||
| Volatility Index | Fair | |||
| Beta / Standard Deviation | IRMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.91 | |||
| Price History | IRMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -3.38% | |||
| 30-Day Total Return | -13.79% | |||
| 60-Day Total Return | -5.21% | |||
| 90-Day Total Return | -2.27% | |||
| Year to Date Total Return | -6.09% | |||
| 1-Year Total Return | 15.77% | |||
| 2-Year Total Return | 40.21% | |||
| 3-Year Total Return | 20.63% | |||
| 5-Year Total Return | 169.20% | |||
| 52-Week High % Change | -16.51% | |||
| 52-Week Low % Change | 31.51% | |||
| Price | IRMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $63.29 | |||
| 52-Week Low Price | $40.18 | |||
| 52-Week Low Price (Date) | Apr 19, 2024 | |||
| 52-Week High Price (Date) | Feb 05, 2025 | |||
| Valuation | IRMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 671.86M | |||
| Enterprise Value | 619.79M | |||
| Price/Earnings (TTM) | 35.24 | |||
| Earnings Per Share (TTM) | 1.50 | |||
| Earnings Per Share Growth | 10.28% | |||
| Price/Earnings To Growth | 3.43 | |||
| Price/Sales (TTM) | 9.24 | |||
| Price/Book (Q) | 7.74 | |||
| Enterprise Value/Revenue (TTM) | 8.46 | |||
| Price | $51.44 | |||
| Enterprise Value/EBITDA (TTM) | 27.20 | |||
| Enterprise Value/EBIT | 28.22 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | IRMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 12.81M | |||
| Dividend Yield | 1.17% | |||
| Div. Per Share (Most Recent) | $0.17 | |||
| Dividend Per Share (TTM) | $0.62 | |||
| Payout Ratio (TTM) | 71.11% | |||
| Dividend Per Share (Most Recent) | $0.17 | |||
| Company Info | IRMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 407 677 8022 | |||
| Address | 1025 Willa Springs Drive Winter Springs, FL 32708 | |||
| Website | www.iradimed.com | |||
| Country | United States | |||
| Year Founded | 1992 | |||
| Profitability | IRMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 29.98% | |||
| Profit Margin | 26.26% | |||
| Management Effectiveness | IRMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 14.41% | |||
| Return on Equity | 24.31% | |||
| Income Statement | IRMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 73.24M | |||
| Total Revenue (TTM) | 73.24M | |||
| Revenue Per Share | $5.72 | |||
| Gross Profit (TTM) | 56.35M | |||
| EBITDA (TTM) | 22.78M | |||
| EBIT (TTM) | 21.96M | |||
| Net Income (TTM) | 19.23M | |||
| Net Income Avl. to Common (TTM) | 19.23M | |||
| Total Revenue Growth (Q YOY) | 11.10% | |||
| Earnings Growth (Q YOY) | 13.37% | |||
| EPS Diluted (TTM) | 1.50 | |||
| EPS Diluted Growth (Q YOY) | 11.48% | |||
| Balance Sheet | IRMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 52.23M | |||
| Cash Per Share (Q) | $4.08 | |||
| Total Current Assets (Q) | 75.24M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 86.82M | |||
| Current Ratio (Q) | 8.839 | |||
| Book Value Per Share (Q) | $6.83 | |||
| Total Assets (Q) | 98.33M | |||
| Total Current Liabilities (Q) | 8.51M | |||
| Total Debt (Q) | 154.70K | |||
| Total Liabilities (Q) | 11.51M | |||
| Total Common Equity (Q) | 86.82M | |||
| Cash Flow | IRMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -8.82M | |||
| Cash from Financing (TTM) | -14.34M | |||
| Net Change in Cash (TTM) | 2.47M | |||
| Levered Free Cash Flow (TTM) | 3.94M | |||
| Cash from Operations (TTM) | 25.62M | |||
